Vimarsana
Biggest News Aggregation in the World

Page 32 - E Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from E Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In E Ltd Today - Breaking & Trending Today

India to be 'Silicon Valley' for vax: US : The Tribune India - Vimarsana News

India to be 'Silicon Valley' for vax: US : The Tribune India

New Delhi, October 25 The United States International Development Finance Corporation (DFC) and Hyderabad-based Biological E Ltd today signed a $50 million financing agreement to expand vaccine manuf

COVID-19 vaccination: A billion doses later, India cannot afford to let its guard down - Vimarsana News

COVID-19 vaccination: A billion doses later, India cannot afford to let its guard down

Celebrations over crossing 1 billion doses should not blunt vigilance against lethal virus

India resumes COVID vaccine export: Neighbouring countries happy - New Delhi Times - India Only International Newspaper - Vimarsana News

India resumes COVID vaccine export: Neighbouring countries happy - New Delhi Times - India Only International Newspaper

On September 20, 2021 – a day before PM Modi’s visit to Washington for Quad summit—Union Health Minister Mansukh Mandaviya declared that India will resume the export of Covid-19 vaccines from October under the Vaccine Maitri initiative. The Quad— geared up to discuss the vaccine issue— welcomed India’s move and pledged to donate 1.2 billion…

BE hopes to roll out COVID-19 vaccine Corbevax by November-end - Vimarsana News

BE hopes to roll out COVID-19 vaccine Corbevax by November-end

Biological E's anti-coronavirus shot, Corbevax, is a RBD protein sub-unit vaccine and is ndergoing phase 2/3 clinical trials on adults

BE hopes to roll out COVID-19 vaccine Corbevax by November-end - Vimarsana News

BE hopes to roll out COVID-19 vaccine Corbevax by November-end

Biological E's anti-coronavirus shot, Corbevax, is a RBD protein sub-unit vaccine and is ndergoing phase 2/3 clinical trials on adults